Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer

Michael D. Green; James L. Speyer; James C. Wernz; Nicoletta Colombo; Uziel Beller; Franco M. Muggia; E. Mark Beckman

doi:10.1007/BF00171850

Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer

Michael D. Green, James L. Speyer, James C. Wernz, Nicoletta Colombo, Uziel Beller, Franco M. Muggia, E. Mark Beckman

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m² intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.

Original language	English
Pages (from-to)	333-336
Number of pages	4
Journal	Investigational New Drugs
Volume	8
Issue number	3
DOIs	https://doi.org/10.1007/BF00171850
State	Published - 1 Aug 1990
Externally published	Yes

Keywords

4′ deoxydoxorubicin
anthracycline
clinical trial
esorubicin
ovarian cancer

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00171850

Cite this

@article{26462ea6f0f04a3bb12fbb2d0f9e4c55,

title = "Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer",

abstract = "Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.",

keywords = "4′ deoxydoxorubicin, anthracycline, clinical trial, esorubicin, ovarian cancer",

author = "Green, {Michael D.} and Speyer, {James L.} and Wernz, {James C.} and Nicoletta Colombo and Uziel Beller and Muggia, {Franco M.} and Beckman, {E. Mark}",

year = "1990",

month = aug,

day = "1",

doi = "10.1007/BF00171850",

language = "English",

volume = "8",

pages = "333--336",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer

AU - Green, Michael D.

AU - Speyer, James L.

AU - Wernz, James C.

AU - Colombo, Nicoletta

AU - Beller, Uziel

AU - Muggia, Franco M.

AU - Beckman, E. Mark

PY - 1990/8/1

Y1 - 1990/8/1

N2 - Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.

AB - Sixteen patients with metastatic ovarian cancer who had not previously been treated with anthracyclines were treated with 4′ deoxydoxorubicin at a dose of 30 mg/m2 intravenously every 3 weeks. There were no clinical responses in this group of patients. Toxicities were infrequent with neutropenia and thrombocytopenia being dose limiting. Nausea and vomiting occurred in only 4 patients. We conclude that 4′ deoxydoxorubicin is an inactive drug in this patient population and does not warrant further investigation in this disease.

KW - 4′ deoxydoxorubicin

KW - anthracycline

KW - clinical trial

KW - esorubicin

KW - ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0025071555&partnerID=8YFLogxK

U2 - 10.1007/BF00171850

DO - 10.1007/BF00171850

M3 - Article

C2 - 2272774

AN - SCOPUS:0025071555

SN - 0167-6997

VL - 8

SP - 333

EP - 336

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II study of esorubicin (4 ′ deoxydoxorubicin) in anthracycline naive patients with ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this